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Abstract
Glioblastoma Multiforme (GBM) is a tumor with high mortality and no known cure. The dramatic molecular and clinical
heterogeneity seen in this tumor has led to attempts to define genetically similar subgroups of GBM with the hope of
developing tumor specific therapies targeted to the unique biology within each of these subgroups. Recently, a subset of
relatively favorable prognosis GBMs has been identified. These glioma CpG island methylator phenotype, or G-CIMP tumors,
have distinct genomic copy number aberrations, DNA methylation patterns, and (mRNA) expression profiles compared to
other GBMs. While the standard method for identifying G-CIMP tumors is based on genome-wide DNA methylation data,
such data is often not available compared to the more widely available gene expression data. In this study, we have
developed and evaluated a method to predict the G-CIMP status of GBM samples based solely on gene expression data.
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Introduction
Glioblastoma Multiforme (GBM) is a deadly brain tumor with
few effective therapies. Identification of the underlying pathogenic
mechanisms involved in the initiation and progression of this
tumor is critical for developing more effective treatments. Recent
studies have demonstrated the profound genetic and molecular
heterogeneity of GBMs. This molecular heterogeneity complicates
the identification of the core elements within the cellular signaling
network of any given GBM thereby limiting out ability to offer
targeted therapies for a specific tumor.
Recent developments in genomic technology (microarray, next
generation sequencing etc.) have enabled a large number of GBMs
to be genetically characterized at unprecedented levels of detail.
Although such studies have revealed the heterogeneity between
GBMs, they have also allowed the identification of subgroups of
tumors that are more closely related than others. A number of
recent studies using supervised and unsupervised analyses have
been published stratifying GBMs into similar subgroups based on
mRNA expression profiles [1,2,3,4].
Our understanding of the epigenome has improved substantially
in the last decade. In particular, epigenetic biomarkers such as
DNA methylation and their effects on tumor biology have been
analyzed in a number of GBM studies [5]. With the recent
development of high-resolution microarray platforms, it is now
possible to measure the level of methylation across an entire
genome. Two such platforms are the Illumina Infinium 27 k and
450 k platforms. These platforms report the methylation ratio
based on methylated and unmethylated probe intensities. The
main difference between these platforms is the number of
methylation sites included. These platforms have been shown to
have high concordance with each other and with bisulfite-
sequencing [6,7,8].
The ability to acquire whole genome-wide DNA methylation
data has opened up the possibility for its use as an alternative
classification methodology, as demonstrated recently in GBM [9].
In this study, the authors describe two clearly separated clusters,
defined as G-CIMP positive and G-CIMP negative, with the G-
CIMP positive group comprising less than 10% of all GBM
samples. As a group, patients with G-CIMP positive GBMs tended
to be younger, have fewer genomic alterations and show better
survival than G-CIMP negative patients. A predominant genetic
feature of G-CIMP positive GBMs is the frequent mutation of
IDH1, which is rarely found in G-CIMP negative GBMs.
Recently, IDH1 mutations have been associated with the altered
methylation profiles in G-CIMP positive gliomas [10].
Secondary to the fact that the G-CIMP status of GBMs
identifies a group of patients with genetically distinct tumors with
very different clinical outcomes, there is an increasing need to
identify such tumors clinically. Unfortunately few clinical or even
research laboratories generate whole genome methylation data on
tumor specimens making the identification of G-CIMP tumors
impossible. By contrast, an increasingly larger number of
laboratories are generating mRNA expression data from their
clinical tumor specimens. In this study, we demonstrate how a
computational algorithm we have devised allows one to identify
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the G-CIMP phenotype of any given GBM at nearly 100%
accuracy using only mRNA expression data.
Materials and Methods
Samples
We used public TCGA (http://cancergenome.nih.gov/) and
REMBRANDT (http://caintegrator-info.nci.nih.gov/rembrandt)
data repositories as our primary source of samples. For
methylation-based validation, we used twenty-one GBMs and
one non-tumor brain sample. Twenty-one GBM samples were
obtained from the prospective NCI-sponsored Glioma Molecular
Diagnostic Initiative (GMDI), which were provided as snap frozen
sections. Pathological diagnosis of these samples was determined
by the local institutional neuropathologist and centrally reviewed
by two NIH neuropathologists who were blinded to the original
diagnosis. Only tumors that met the criteria of having a consensus
pathological diagnosis from the NIH neuropathologists were
utilized for our analyses. The one non-tumor sample was obtained
from a medically indicated therapeutic temporal lobe resection
from an NIH patient with refractory epilepsy.
Methylation Experiment
We isolated DNA from cell pellets and fresh frozen tumor tissue
using the QIAmp DNA micro kit (Qiagen). One microgram of the
DNA was bisulfite converted and processed on Human Methyl-
ation450 BeadChips (Illumina) using the Infinium HD Methyla-
tion Assay as described previously [11]. We interrogated 485,000
individual CpG sites per sample at single-nucleotide resolution.
Image data were extracted and analyzed using the GenomeStudio
v2010.3 methylation module (Illumina).
Data Sets
TCGA methylation data set. We used level-2 methylation
data from Illumina Infinium 27 k and 450 k platforms. For the
27 k methylation data we filtered 23,487/27,578 sites with no
missing values on non-sex chromosomes. Similarly there were
486,412 methylation sites with no missing values retained in 450 k
methylation data. We found 22,270 of these methylation sites to be
shared between 27 k and 450 k platforms.
Methylation data sets from both platforms based on common
methylation sites were then filtered to 1509 sites which had a
standard deviation of 0.2 or greater as in [9]. There were 368
samples and 1509 methylation sites in our final TCGA methyl-
ation data set.
TCGA expression data set. We imported 413 Affymetrix
U133A samples (raw data) using RMA from the TCGA portal
(RMA background correction, quantile normalization, median
polish). There were 403 GBM and 10 normal brain samples in this
data set. We performed unsupervised clustering based on 1670
probe sets (std. dev. 1) to check if any GBM samples cluster with
normal samples due to possible normal tissue contamination.
Three samples clustered with normal brain samples and were
excluded from data set (Figure S1).
NOB expression data set. We used gene expression data for
201 GBM and 31 normal brain samples in the NOB database.
Most of these samples have been publicized in REMBRANDT
public repository previously [12]. These samples were generated
using Affymetrix U133 plus 2.0-microarray platform using the 1-
cycle protocol. We normalized the data using RMA (RMA
background correction, quantile normalization, median polish).
We performed unsupervised clustering on 2178/54,675 high
variation (standard deviation.1) probe sets. We detected 27 GBM
samples, which clustered with normal samples. These samples
were excluded due to likely normal brain contamination (Figure
S2).
NOBmethylation data set. Raw methylation data imported
using GenomeStudio Software (include ref version). Methylation
sites, which have detection p-value less than 0.05 for all samples,
have been retained.
Batch Removal
We used a mixed model ANOVA based algorithm by Partek
6.6beta (PartekTM software (Partek Inc., St. Charles, MI)) to
remove the batch effects between TCGA and NOB gene
expression data sets. To measure the efficiency of batch effect
removal, we used gene expression data for normal brain samples.
We assumed that normal brain samples in both data sets would
cluster together in a combined data set if the batch effect removal
were successful.
There were two variables within the ANOVA model that were
used for batch removal. These variables are sample origin (TCGA
or NOB) and tissue origin (GBM or normal). We first showed that
normal brain samples from two different data sources cluster
together after batch effect removal; from this we concluded that
the batch effect removal was successful. We then excluded non-
tumor samples from both data sets and applied batch effect
removal on sample origin to obtain final data set.
Hierarchical Clustering (HC) and Principle Component
Analysis (PCA)
We used Partek Software (6.6 beta,Partek Inc., St. Charles, MI)
to perform HC and PCA. Average linkage and Euclidean distance
were used for all HCs. Expression data was standardized by
sample columns prior to performing the HC, although this was not
done for the methylation data. PCAs were performed using
correlation dispersion matrix and normalized eigenvector scaling.
G-CIMP Prediction Based on Expression Data
We generated five prediction models, which differ only by the
use of the top number of differentially expressed probe sets (10, 25,
50, 100 and 200). All models used nearest neighbor algorithm,
which classifies unknown samples based on the closest known
sample. Euclidean distance was used as the distance measure. We
used the Partek implementation of this algorithm. Probe sets
included in these five models are provided as supplementary files
(Table S1, S2, S3, S4, S5).
Results
Unsupervised Clustering of TCGA Samples Based on
Methylation Data
We obtained TCGA methylation data for 368 GBM samples
and performed unsupervised clustering to identify G-CIMP status
of these samples as described in [9] (see Materials and Methods).
We applied partition clustering with different number of clusters
(2–5) and obtained the best performance (Davies-Boudin Score) by
clustering into two groups (Figure S3).
We labeled the larger cluster (338 samples) as G-CIMP negative
and the smaller cluster (30 samples) as G-CIMP positive (Figure 1).
TCGA recently released a Data Freeze package, which includes
the G-CIMP calls (TCGA Analysis Working Group Data Release
Package, 9/3/2011, https://wiki.nci.nih.gov/display/TCGAM/
Datasets+GBM). 365 of the 368 samples we analyzed had an
existing G-CIMP classification in the TCGA package. Out of the
365 samples, only four samples were found to have contradicting
labels, i.e. they are labeled as G-CIMP positive in TCGA and as
G-CIMP Prediction for GBM Using Expression Data
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G-CIMP negative in our list (Table 1). According to our
unsupervised analysis, these samples are clearly clustered with
G-CIMP negative samples (Figure S4). Thus, we decided to keep
these samples in our subsequent analyses.
Prediction of G-CIMP Calls of TCGA Samples from
Expression Data
There are many samples in the TCGA repository where mRNA
expression data is available but more comprehensive genome-wide
methylation data (27 k or 450 k) is not available. We hypothesized
that the G-CIMP calls of these GBM samples could be predicted
based on gene expression data. To test this hypothesis, we used the
gene expression data set for samples with available G-CIMP calls
(based on methylation) as the training data. After training five
prediction models, we predicted the G-CIMP status of the subset
of TCGA samples that had available expression data but not
methylation data. The difference between these five models was
the use of either the top 10, 25, 50, 100 or 200 differentially
expressed probe sets between the G-CIMP positive and negative
groups, respectively.
We obtained expression profiles of 403 GBMs and ten normal
brain samples using the Affymetrix U133A platform from the
TCGA data repository. We performed a principal component
analysis and observed that three of the GBM samples cluster with
normal brain samples (Figure S5). These samples were eliminated
in our analysis due to possible contamination with normal brain
tissue.
The G-CIMP status of 218 out of 400 GBM samples was
available from methylation-based classifications (last section).
Before predicting the G-CIMP status of the remaining samples,
we used samples with available G-CIMP data to measure the
prediction performance on expression data by applying a method
called two-fold cross validation. Briefly, we divided the sample set with
known G-CIMP status into two groups and labeled one of these
groups as the training set and the other group as the test set. We
developed a prediction model based on the expression data of the
training set and applied this model on the test set (see Materials
and Methods). Then, we compared the real labels with predic-
tions. We repeated this operation by changing the training and test
sets. We obtained 100% prediction accuracy rate in the cross-
validation (Table S6).
Figure 1. PCA plot for TCGA samples based on methylation data (Blue: G-CIMP positive, red: G-CIMP negative samples). 1509
methylation sites (std. dev. .0.2) have been shown.
doi:10.1371/journal.pone.0047839.g001
Table 1. Comparison of TCGA G-CIMP labels and our G-CIMP calls.
TCGA G-CIMP positive TCGA G-CIMP negative TCGA UNKNOWN
Predicted G-CIMP positive 30 0 0
Predcited G-CIMP negative 4 331 3
doi:10.1371/journal.pone.0047839.t001
G-CIMP Prediction for GBM Using Expression Data
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After validating the performance of our prediction algorithm,
we used it to predict the G-CIMP status of the subset of TCGA
samples that did not have methylation data. Following our
prediction, there were 30 G-CIMP positive and 370 G-CIMP
negative samples in the TCGA expression data set.
Prediction of G-CIMP Calls Using an Alternate Data Set
(REMBRANDT)
In order to evaluate the robustness of our prediction algorithm,
we obtained gene expression profiles of 174 GBM samples in the
NOB/REMBRANDT database after contamination filtering (see
Materials and Methods). We combined the NOB expression data
set and the TCGA expression data set using 22,277 common
probe sets. We observed a significant batch effect between TCGA
and NOB gene expression data sets (Figure S6, Figure S7). This
result is expected because the TCGA data set is based on the
Affymetrix U133A platform using the IVT labeling protocol, while
the NOB data set is based on the Affymetrix U133 Plus 2.0
platform and 1-cycle target labeling protocol (www.affymetrix.
com). We removed this batch effect by using an ANOVA based
batch effect removal algorithm (see Materials and Methods).
After batch effect removal, the separation between TCGA and
NOB samples diminished and normal brain samples from both
data sets clustered together which shows the adequacy of the batch
effect removal (Figure S6, Figure S7 versus Figure S8, Figure 2).
We constructed our training and test sets as follows (Figure 3):
we imported and normalized CEL files using RMA for each data
set independently (400 TCGA samples and 174 NOB samples)
and selected only the common 22,227 probe sets. We repeated the
batch effect removal step between TCGA and NOB data sets
without including the normal brain samples. We assumed that the
batch effect removal would be more successful without normal
samples as the data sets become more homogeneous without
normal samples. We assigned the TCGA data as the training set
and the NOB data as the test set.
We then built five different prediction models based on the
training set (i.e., TCGA dataset) using the top 10, 25, 50, 100, and
200 differentially expressed probe sets between G-CIMP positive
and negative samples. We repeated the two-fold cross-validation
within the TCGA expression data set. The two-fold cross-
validation in the previous section would not suffice since (i) earlier
cross-validation was within only 218 GBM samples, and (ii) the
gene expression data set had been manipulated substantially with
the batch effect removal. The cross-validation results achieved
99.75% accuracy for all models.
We applied all five models on NOB samples to predict their G-
CIMP status. Five models agreed on 10 samples as G-CIMP
positive and 159 samples as G-CIMP negative. There was no
consensus for the remaining five samples, which were labeled as
Non-Consistent (NC).
Clinical Validation
It has been previously demonstrated that there are significant
age and survival differences between patients with G-CIMP
positive and G-CIMP negative GBMs [9]. In our analysis, the
median age for TCGA G-CIMP positive GBMs was 36 compared
to the median age for TCGA G-CIMP negative GBMs that was
59 (t-test p-value ,1.628e-15). Similarly, the median age for the
predicted NOB G-CIMP positive GBMs was 38 compared to
56 years for the median age of G-CIMP negative GBMs (t-test p-
value ,2.1968e-05) (Figure 4).
Figure 2. PCA plot of TCGA and NOB samples after batch effect removal. As expected, normal brain samples are clustered together, and
TCGA and NOB samples are not separated. We used high variation 1482 probe sets (std. dev. .1) in combined data set.
doi:10.1371/journal.pone.0047839.g002
G-CIMP Prediction for GBM Using Expression Data
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The calculated median survival for TCGA G-CIMP positive
GBMs in our analysis was 840.5 days whereas the median survival
for TCGA G-CIMP negative GBMs was 327 days (Wilcoxon-
Gehan p-value ,1.10279e-05). Consistent with these data, the
calculated median survival for the predicted G-CIMP positive
NOB samples was 1121 days whereas median survival for
predicted G-CIMP negative NOB samples was 470 days
(Wilcoxon-Gehan p-value ,0.0103) (Figure 5). These results show
that, as expected, predicted NOB G-CIMP positive patients were
younger and survived significantly longer than predicted NOB G-
CIMP negative patients. Moreover, the median age and survival of
NOB G-CIMP positive/negative and TCGA G-CIMP positive/
negative samples are very similar, respectively.
Validation of G-CIMP Prediction by Methylation Assay
We used the Illumina Human Methylation 450 K platform to
generate methylation data on a subset of the NOB samples to
validate our predictions. We selected nine G-CIMP positive
samples, seven G-CIMP negative samples, all five NC samples,
and one normal brain sample for the methylation assays (see
Materials and Methods).
We combined our methylation data set with the TCGA
methylation data set methylation data from four normal brain
samples provided by USC Epigenome Center (http://epigenome.
usc.edu). In this combined data set, 1438 out of 1509 methylation
sites passed through our detection filter.
First, we checked if there was a batch effect since the data sets
came from different groups (i.e., NOB vs. TCGA). We observed
that normal samples clustered tightly in the combined data set
suggesting that the batch effect between data sets was minimal
(Figure 6). After demonstrating the lack of a significant batch effect
in the combined data set, we compared expression-based G-CIMP
labels to methylation-based G-CIMP labels. We observed that in
general, predicted G-CIMP positive samples clustered with TCGA
G-CIMP positive samples and predicted G-CIMP negative
samples clustered with TCGA G-CIMP negative samples based
on methylation data (Figure 6). We then classified our methylation
samples into G-CIMP subtypes using the TCGA samples as the
training set, using nearest neighbor algorithm, Euclidean distance
and all 1438 methylation sites. We found 100% accuracy in a two-
fold cross validation of TCGA GBM samples. We found only one
mis-prediction in our samples; one G-CIMP negative sample (on
methylation data) had been predicted as G-CIMP positive (on
expression data).
We noticed that the mis-predicted sample and a majority of the
NC samples fell between the two G-CIMP methylation clusters
(Figure 6). In the original TCGA methylation data set, the two G-
CIMP clusters were clearly separated with no samples showing an
intermediate methylation profile. This made us suspicious about
these samples that fell between the G-CIMP positive and G-CIMP
negative clusters. We reevaluated twelve NOB samples based on
clinical reports (Figure 7). Six of these twelve samples were
ambiguous (5 NC and one mis-predicted) and remaining six were
non–ambiguous. Five of the six non-ambiguous samples were
GBMs and remaining one was Anaplastic Astrocytoma. On the
other hand, all six ambiguous samples were discovered not to be
GBMs. Thus, the difficulty in classifying some of the samples was
determined to be related to poor sample labeling. Thus, our
prediction algorithm was found to have 100% accuracy for
correctly labeled GBM samples.
Of interest, we observed many NCs when we tried to classify
non-tumor samples into G-CIMP subtypes. Thus, it appears that
our classification system has difficulty in characterizing non-GBM
pathology. This probably reflects the fact that G-CIMP biology is
unique to GBMs and cannot be applied to other tumor types and/
or normal tissue.
Methylation Status and Biological Interpretation of the
Genes in the Prediction Models
In order to evaluate the methylation status and perform
functional enrichment analysis for the genes in our prediction
models we first analyzed the genes in prediction models in terms of
methylation difference between G-CIMP positive and G-CIMP
negative subtypes. Next, we analyzed the genes in the prediction
Figure 3. Data processing flowchart for predicting G-CIMP calls of NOB samples from TCGA gene expression data.
doi:10.1371/journal.pone.0047839.g003
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models in terms of methylation-expression correlation. Finally, we
uploaded the genes in our prediction models to Ingenuity Pathway
Analysis (IPA) to inquire whether these genes show enrichment for
specific biological processes.
Our prediction models used probe sets, which represent mRNA
expression. By contrast, methylation data is based on the
methylation ratio of a site on a given gene. We combined these
two data types at the gene level. We converted the probe sets to
gene names and generated six categories based on the existence of
genes in our prediction models as follows. If a gene is included in
our first prediction model with ten probe sets, it is assigned in the
first category, which is denoted by top10. If it is not in the first
prediction model but in the second prediction model, which has
twenty-five probe sets, it is in the second category, which is
denoted by top11–25. Similarly, we created three more categories
denoted by top26–50, top51–100 and top101–200. If a gene is not
included in any of the five prediction models we used, it is assigned
to the last category, which is denoted by not-in-lists.
After defining the categories, we compared the methylation
status for the genes in each category. First, we calculated the
median methylation for each methylation site, for G-CIMP
positive group and G-CIMP negative group. Accordingly, we
used the Beta-values in TCGA methylation data set we had
created (Beta values roughly represent the ratio between methyl-
ated and unmethylated probe intensities.). Then, we measured the
absolute median methylation difference by subtracting these
numbers and taking the absolute value. Next, we compared the
genes in six categories in terms of absolute median methylation
difference. We observed that genes we used in prediction models
indicated higher methylation difference compared to genes that
are not included (Figure S9).
We next compared the methylation-expression correlations
among the six categories by computing the methylation-expression
Pearson correlation for each methylation site using Beta-values
and TCGA Level-3 expression data (Agilent Platform). When we
compare the methylation-expression correlations for the genes in
the six categories, we observed a strong negative correlation for the
genes in our prediction models (Figure S10). These results
demonstrate that selected genes have clear methylation differences
and these differences are reflected on gene expression.
We next used IPA to assess the functional enrichment for the
genes in our prediction models. We identified the genes that are
included in the prediction model with 200 probe sets and uploaded
these genes to IPA along with the gene names and expression fold
changes between G-CIMP positive and G-CIMP negative samples
using TCGA expression data set. IPA reported only one significant
function in its functional enrichment module, that being an
increase in ‘proliferation of cells’ associated genes in G-CIMP
negative GBMs. This result is consistent with the poor survival rate
of G-CIMP negative GBM patients. In the transcription factor
activity module, IPA identified KDM5B (lysine (K)-specific
demethylase 5B) as the most significantly altered transcription
factor. According to IPA report, KDM5B is activated in G-CIMP
positive samples. It is interesting to observe a demethylase with
increased activity in G-CIMP subtype considering the altered
methylation profile in this subtype [10].
Figure 4. Box-Whisker plot of age of NOB and TCGA G-CIMP positive and G-CIMP negative samples. Limits of box and whiskers plot are
10%, 25%, 50%, 75% and 90%.
doi:10.1371/journal.pone.0047839.g004
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Importance of Proper Subtyping
Although the literature is replete with studies finding correla-
tions between patient clinical outcome (e.g. survival) and specific
genotypes (e.g. gene expression, chromosomal number variations),
the majority of such studies have treated GBM as a homogeneous
disease. This approach might have led to false interpretations if
different genomic subtypes of GBM have different clinical
outcomes. For instance, it is possible that some of these
‘‘survival-specific’’ genes in GBM could be enriched for in G-
CIMP tumors. Similarly, a disproportionate number of patients
with G-CIMP positive or negative tumors could influence the
outcome of a clinical trial and be falsely interpreted as a
therapeutic effect.
To measure the effect of G-CIMP status on survival, we ran a
Cox-regression for all genes with and without the G-CIMP
samples. We found 200 and 3 survival-correlated probe sets in
TCGA (n = 391) and the NOB data (n = 134), respectively with a
FDR,0.05 (Benjamini-Hochberg step-up multiple test correction
[13]). We could not find any survival-correlated probe sets in both
data sets after removing G-CIMP positive samples. This suggests
that all survival-related genes we identified were related to their
disproportional representation in the G-CIMP tumors and the
overall improved survival of this group of patients.
Using less stringent criteria (p,0.05) to measure the G-CIMP
effect on survival, we found by a Cox-regression analysis 3258
probe sets related to survival for all samples with survival
information (n = 391) in the TCGA data set. By contrast, there
were only 986 probe sets related to survival when G-CIMP
positive samples were excluded (n = 361, 489 probe sets are shared
between two lists). Similarly, using NOB data we found 2377
probe sets related to survival for all samples (n = 134) but only
1142 probe sets for G-CIMP negative samples (n = 123, 937 probe
sets are shared between two lists).
These results show that more than 84% of the survival-related
probes sets in the initial TCGA dataset are changed when G-
CIMP positive samples are removed (60% in the NOB dataset).
Moreover the number of survival-related probe sets identified is
reduced by 70% after removing G-CIMP samples in the TCGA
data set and by 52% in the NOB data set. Although reducing the
sample size will lower the statistical power to identify survival
related probe sets, the less than 8% reduction in sample size is
unlikely to be responsible for the large decrease in survival related
probe sets when we look only at G-CIMP negative tumors. In
order to roughly measure the affect of sample size on the number
of survival related probe sets, we randomly deleted ,10% (36/
361) of G-CIMP negative samples and repeated the analyses. In
the new data set, 39% of probe sets have been changed (381 out of
986 probe sets) and the number of probe sets has been reduced by
only 10% (986 to 881 probe sets).
Discussion
In this study, we have established a method to classify GBM
samples into G-CIMP subtypes based on gene expression data. As
expected, we have observed a high concordance between the
TCGA G-CIMP groups and predicted NOB G-CIMP groups in
Figure 5. Kaplan-Meier survival plot for NOB G-CIMP+ (n=7), NOB G-CIMP2 (n =123), TCGA G-CIMP+ (n=30) and TCGA G-CIMP2
(n =361) samples.
doi:10.1371/journal.pone.0047839.g005
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terms of age and survival. We have also validated the methylation
differences between NOB G-CIMP positive and negative samples
by performing in vitro methylation assays. These results demon-
strate that the G-CIMP subtypes are distinct and can be
reproducibly validated on a totally independent data set. An
alternative approach to identify G-CIMP positive GBMs would be
to check for IDH1 mutations. However, a small but significant
subset of G-CIMP positive GBMs (5/23 in [9]) do not carry this
mutation thus reducing the accuracy of such an approach.
We used the TCGA Affymetrix U133A data set as training data
because the NOB expression data was based on the Affymetrix
U133PLUS2.0 platform which uses a similar technology to
U133A. TCGA has expression data on multiple platforms such
as the Agilent 244 K G4502A and Affymetrix Human Exon 1.0
platforms. Investigators interested in adopting our method for G-
CIMP classification and have expression data from any of the
array platforms used by TCGA can simply apply our methods by
using the corresponding TCGA data set as training data.
Since multidimensional clustering algorithms are able to
produce subclasses even on random data, it is important to
validate clusters on an external dataset. There are well-known
differences between microarray data produced in different settings
(lab, platform, protocol) [14]. These batch effects can limit the
reproducibility of observed subtypes in external data sets unless the
differences across the subtypes are large enough. This limitation
holds for other biological results besides subtypes. Although
independent validation takes time, without such validation one is
likely to report a number of false positives. Accordingly, recent
reports [15,16] have shown limited reproducibility among multiple
microarray studies. A recent study explored the possible causes for
the lack of consensus in attempting to derive expression-based
subtypes of GBM [17].
Batch effects can be removed via two general mechanisms. One
of these involves running identical specimens (also called batch
controls) on both data sets. Both data sets could then be scaled to
make these identical specimens equivalent on the combined data
set. Another method involves combining data sets based on a
representation assumption. If two data sets are large enough, then
sampling the same population allows one to assume they represent the
same entity. In this case, we can apply batch effect removal
algorithms that scale the data sets and make them statistically
comparable. However, if data sets are not large enough or they are
not derived from identical populations, then the representation
assumption fails and the results will be flawed. In this instance, a
GBM data set may not be combined with a general brain tumor
data set although one population is the subset of the other.
Similarly we cannot combine two GBM data sets that contain
tumors from patients with disproportionate distributions of age or
sex unless we show that there is no molecular difference between
these different clinical groups.
In this vein, the establishment of gene classifiers is also based on
the assumption that the original data on which the classifiers were
developed and the new data on which the classifiers are to be used,
represent the same entity. If data sets are not large enough or they
represent different populations this operation would be flawed and
might lead to false interpretations. For example, if a gene
signature, which separates different subsets of GBM is applied to
a general brain tumor data set, results are likely to be unreliable.
We saw this in our analysis where our G-CIMP classifiers gave us
indeterminate results when we used them to attempt to classify
non-GBM gliomas and normal brain tissue.
Figure 6. PCA plot of TCGA and NOB samples in combined methylation data set. This data set includes 394 samples and 1438 methylation
sites.
doi:10.1371/journal.pone.0047839.g006
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One issue that would potentially negatively affect the accuracy
of our analysis concerns the origin of the tumor samples. The
TCGA samples are generally selected from untreated primary
GBMs while the NOB tumor samples are mostly previously
treated and recurrent GBMs. Interestingly, our analyses demon-
strate that this difference did not affect our ability to identify the
G-CIMP subtypes. In fact, the similarity between TCGA and
NOB data in terms of age and survival profiles of the derived G-
CIMP positive and G-CIMP negative groups were excellent.
Unlike the situation with gene expression data, we did not
observe any separation or batch effect between the two un-
normalized methylation data sets but rather found that the non-
tumor samples from both data sets clustered tightly. This positive
outcome suggests that Infinium methylation data sets from
different labs are comparable without data manipulation. This is
a major advantage that will allow increasing statistical power for
future analyses by creating larger data sets by combining multiple
smaller data sets.
Identifying and assigning patient-specific tumors to stable
genetic sub-types in heterogeneous diseases like GBM will be an
important step towards personalized medicine. Alternative ther-
apeutic regimes can be developed for different subtypes, and
should target subtype specific vulnerabilities. Establishing the
stability and reproducibility (universality) of these subtypes is a
critical step in achieving this goal. Our study demonstrates that G-
CIMP methylation subtypes are stable enough to be independently
validated through gene expression array data despite strong batch
effects. Moreover we demonstrate that the prognostic significance
of the G-CIMP subtype is very consistent, even when evaluated
across two totally independent large cohorts of patients. This result
suggests that identification of the G-CIMP will have significant
clinical relevance for clinical trial design stratification, patient
prognosis and potentially treatment in the future.
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